<DOC>
	<DOCNO>NCT02081937</DOCNO>
	<brief_summary>Patients receive anti-CD19-CAR ( couple CD137 CD3 zeta signal domain ) vector-transduced autologous T cell period 4 5 consecutive day escalate dose . After completion study treatment , patient follow intensively 6 month , every 3 month 2 year , annually thereafter 10 year .</brief_summary>
	<brief_title>CART-19 Immunotherapy Mantle Cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine safety efficacy chimeric antigen receptor T cell transduce anti-CD19 ( cluster differentiation antigen 19 ) vector ( refer CART-19 cell ) elderly patient MCL . II . Determine duration vivo survival CART-19 cell . RT-PCR ( reverse transcription polymerase chain reaction ) analysis whole blood use detect quantify survival CART-19 TCR ( T-cell receptor ) zeta : CD137 TCR zeta cell time . SECONDARY OBJECTIVES : For patient detectable disease , measure anti-tumor response due CART-19 cell infusion . Estimate relative traffic CART-19 cell tumor bone marrow lymph node . Determine cellular humoral host immunity develop murine anti-CD19 , assess correlation loss detectable CART-19 ( loss engraftment ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Male female CD19+ relapse refractory MCL , available curative treatment option ( autologous allogeneic SCT ) limit prognosis ( several month &lt; 2 year survival ) currently available therapy enrol . Not eligible appropriate conventional allogeneic SCT Patients achieve partial response FCR ( fludarabine , cyclophosphamide Rituxan ) initial therapy eligible . Beyond 1st CR ( complete remission ) relapse persistent disease eligible appropriate conventional allogeneic autologous SCT Disease respond stable recent therapy ( chemotherapy , MoAb , etc ... ) Relapsed prior autologous SCT Residual disease primary therapy eligible autologous SCT Relapsed prior autologous SCT Beyond 1st CR relapse persistent disease eligible appropriate conventional allogeneic autologous SCT Expected survival &gt; 12 week Creatinine &lt; 2.5 mg/dl ALT ( alanine aminotransferase ) /AST ( aspartate aminotransferase ) &lt; 3x normal Bilirubin &lt; 2.0 mg/dl Any relapse prior autologous SCT make patient eligible regardless prior therapy Adequate venous access apheresis , contraindication leukapheresis Voluntary inform consent give â€¢ Pregnant lactate woman . The safety therapy unborn child know . Female study participant reproductive potential must negative serum urine pregnancy test perform within 48 hour infusion . Uncontrolled active infection Active hepatitis B hepatitis C infection Concurrent use systemic steroid . Recent current use inhale steroid exclusionary Previously treatment gene therapy product Feasibility assessment screen demonstrates &lt; 30 % transduction target lymphocytes , insufficient expansion ( &lt; 5fold ) response CD3/CD137 costimulation Any uncontrolled active medical disorder would preclude participation outline HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>chimeric antigen receptor</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>T lymphocyte</keyword>
	<keyword>mantle cell lymphoma</keyword>
</DOC>